Fig. 7.

Entrainment by cysteine administration is prevented in PPP-treated mice. (a) Experimental schedule. The green arrows indicate oral administration time of 0.5% CMC (Control) or Cysteine at ZT 5 for 3 consecutive days. The red arrows indicate time of treatment with the IGF-1R blocker PPP at ZT 6.5 for 3 consecutive days. The orange arrow indicates fasting. (b) The left graph shows average relative waveforms of hepatic in vivo PER2::LUC bioluminescence in all groups. The right graph shows average peak phases of in vivo PER2::LUC rhythms. Control: n = 5; Cysteine + DMSO: n = 5; Cysteine + PPP: n = 4. Data are presented as the mean ± SEM. ^%P < 0.05, ^%%P < 0.01 (vs. Control), ^&P < 0.05 (vs. Cysteine + DMSO) by two-way ANOVA with Tukey post-hoc test, and ^$P < 0.05 (vs. Control) by one-way ANOVA with Tukey post-hoc test.